Welcome to our dedicated page for Eloxx Pharmaceuticals SEC filings (Ticker: ELOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eloxx Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eloxx Pharmaceuticals's regulatory disclosures and financial reporting.
Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju reported beneficial ownership of Eloxx Pharmaceuticals, Inc. common stock. Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., and Samsara Opportunity Fund GP, LLC each report beneficial ownership of 201,793 shares, representing 5.0% of Eloxx’s common stock.
Dr. Srinivas Akkaraju reports beneficial ownership of 403,586 shares, or 9.99% of the common stock, based on 4,036,314 shares outstanding as of June 10, 2026. The position includes, for each of Samsara LP and Samsara Opportunity Fund, 200,000 shares of common stock and Pre-Funded Warrants exercisable for up to 250,000 shares, subject to a 9.99% Beneficial Ownership Blocker that limits warrant exercise above that ownership level.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Eloxx Pharmaceuticals, Inc..
As of June 30, 2026, the reporting persons may be deemed to beneficially own 400,000 shares of Eloxx common stock, representing 9.91% of the outstanding class. They report 0 shares with sole voting or dispositive power and 400,000 shares with shared voting and shared dispositive power. BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or direct dividends and sale proceeds from more than five percent of these shares.
Eloxx Pharmaceuticals reported second quarter 2026 results and a business update, highlighting a significantly strengthened balance sheet following a public offering with gross proceeds of $66.0 million and an uplisting to the Nasdaq Capital Market. As of June 30, 2026, cash and cash equivalents were $62.0 million, including approximately $58.3 million in net proceeds from the June 2026 offering, and the company stated this cash is expected to fund operations into mid‑2028. Total stockholders’ equity improved to $46.4 million from a deficit of $(11.9) million at year‑end 2025.
For the three months ended June 30, 2026, net loss was $4.5 million, or $(0.66) per share, compared with $1.9 million, or $(5.45) per share a year earlier. Research and development expense rose to $2.8 million from $0.9 million, and general and administrative expense increased to $1.6 million from $0.7 million, mainly from higher clinical trial, personnel, and professional fees. For the first half of 2026, net loss was $8.3 million versus $3.6 million in 2025. In May 2026, the company completed a one‑for‑eleven reverse stock split and reduced authorized common shares from 500,000,000 to 100,000,000, and continues to advance its lead candidate exaluren in rare kidney disease indications.
Eloxx Pharmaceuticals, Inc. reported a net loss of $4.5 million for the quarter and $8.3 million for the six months ended June 30, 2026, up from $1.9 million and $3.6 million in the prior-year periods, driven by higher research and development and general and administrative expenses. Cash and cash equivalents rose to $62.0 million from $4.8 million at December 31, 2025, reflecting a $58.3 million June 2026 public offering and additional pre-funded warrant financings, which also eliminated remaining Hercules debt.
Total assets increased to $63.4 million and stockholders’ equity turned positive at $46.4 million, compared with a deficit of $11.9 million at year-end 2025. The company is advancing its lead candidate exaluren for rare kidney diseases, preparing a Phase 2b trial in nonsense mutation Alport syndrome in 2026 and a Phase 2 trial in nmADPKD in 2027, and remains eligible for up to $470.0 million in milestones plus royalties under its ZKN-013 license with Almirall. Management believes current liquidity will fund operations for at least 12 months, but a previously identified material weakness in internal control over financial reporting related to the financial close and reconciliation process remains under remediation.
Aberdeen Group plc and its subsidiary abrdn Inc. report beneficial ownership of Eloxx Pharmaceuticals Inc. common stock. They state beneficial ownership of 400,000 shares of common stock, representing 9.91% of the class.
Both Aberdeen Group plc and abrdn Inc. report 0 shares with sole voting or dispositive power and 400,000 shares with shared voting and shared dispositive power. The filing notes that abrdn Inc. beneficially owns these shares on behalf of underlying clients, with Aberdeen Group plc as the parent and abrdn Holdings Limited as the intermediate holding company.
Eloxx Pharmaceuticals disclosed that Coastlands-related reporting persons collectively beneficially own 410,530 shares of Common Stock, representing 9.99% of the class. The filing states the calculation uses 4,036,314 shares outstanding as of June 10, 2026 from the issuer's final prospectus.
The reported position comprises 337,431 shares owned and 73,099 shares issuable upon exercise of pre-funded warrants, with the 9.99% beneficial ownership limitation applied and excess pre-funded warrants excluded.
Eloxx Pharmaceuticals ownership disclosure: A group of related investment entities and Daniel Simon report shared beneficial ownership of common stock totaling individual stakes up to 854,973 shares (19.99%) as of filings signed 06/17/2026. The filing states these securities are directly owned by advisory clients of Domicilium Capital Partners LLC.
The schedule lists multiple related holders with reported holdings: BKJLAGG, LLC 602,266 shares (14.1%), and several entities holding between 238,422 and 240,688 shares. The filing notes a 19.99% beneficial ownership limitation and excludes pre-funded warrants in excess of that limit.
Eloxx Pharmaceuticals, Inc. reported that 10% owner Domicilium Real Estate Fund III LP, through affiliated investment entities, restructured its position in pre-funded warrants and common stock. Several transactions coded "J" as "other acquisition or disposition" reflect exchanges of Pre-Funded Warrants into common shares pursuant to their terms.
Footnotes state that each Pre-Funded Warrant was exchanged for one share of Eloxx common stock and that the warrants have no expiration date and are exercisable at any time, subject to a 19.99% beneficial ownership cap. All holdings are reported as indirect, through funds and LLCs advised by Domicilium and managed by Daniel Simon. No open-market purchases or sales are reported in this filing.
Domicilium Real Estate Fund III LP filed an initial ownership report for Eloxx Pharmaceuticals, Inc. as a greater-than-10% holder. The filing shows indirect ownership of 14,285 shares of Eloxx common stock.
The fund also indirectly holds several Pre-Funded Warrants to purchase Eloxx common stock, with underlying share amounts of 611,317, 361,578, 1,196,067 and 238,422 shares. These warrants are exercisable at an exercise price of $0.1100 per share and have no expiration date. A footnote states that holders may not exercise Pre-Funded Warrants if, after exercise, they would beneficially own more than 19.99% of Eloxx’s outstanding common stock.
The securities are held through entities including Domicilium Real Estate Fund III LP, BKJLAGG, LLC, MSEK Charleston LLC and Bold Stroke Investments, LLC, and may be deemed indirectly beneficially owned by Domicilium Capital Partners LLC, its affiliates and Daniel Simon.
Eloxx Pharmaceuticals, Inc. Schedule 13G filing shows EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman reporting shared beneficial ownership of common stock. The filing lists 403,586 shares (EcoR1 and Mr. Nodelman) and 377,635 shares (Qualified Fund), representing 9.9% and 9.3% of the class respectively. The percentages are calculated using 4,036,314 shares outstanding following an offering disclosed in a prospectus filed 06/09/2026. The reporting persons state the holdings were not acquired to change control and disclaim group membership beyond the joint filing.